ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Knight Therapeutics Inc

Knight Therapeutics Inc (GUD)

5.30
-0.14
(-2.57%)
Closed March 29 04:12PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
5.30
Bid
5.25
Ask
5.40
Volume
35,930
5.30 Day's Range 5.48
4.28 52 Week Range 5.75
Market Cap
Previous Close
5.44
Open
5.41
Last Trade
18
@
5.3
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
79,400
Shares Outstanding
112,206,000
Dividend Yield
-
PE Ratio
-19.89
Earnings Per Share (EPS)
-0.27
Revenue
297.59M
Net Profit
-29.89M

About Knight Therapeutics Inc

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Montreal, Quebec, Can
Founded
1970
Knight Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the Toronto Stock Exchange with ticker GUD. The last closing price for Knight Therapeutics was $5.44. Over the last year, Knight Therapeutics shares have traded in a share price range of $ 4.28 to $ 5.75.

Knight Therapeutics currently has 112,206,000 shares outstanding. The market capitalization of Knight Therapeutics is $594.69 million. Knight Therapeutics has a price to earnings ratio (PE ratio) of -19.89.

GUD Latest News

Knight Therapeutics Inc. ranks on The Globe and Mail’s fifth-annual Women Lead Here benchmark of executive gender diversity

MONTREAL, March 28, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”) is pleased to announce it will be recognized on The Globe and Mail’s 2024 Report on...

Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results

MONTREAL, March 21, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported...

Notice of Knight Therapeutics' Fourth Quarter and Year End 2023 Results Conference Call

MONTREAL, March 14, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and...

Knight Therapeutics Announces Launch of Minjuvi® in Brazil

MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of Minjuvi®...

Knight Therapeutics Inc. Celebrates its First Decade of Success

MONTREAL, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it is marking its...

Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil

MONTREAL, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian...

Knight Therapeutics Announces Launch of Bijuva® in Canada

MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a Pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of BIJUVA®...

Knight Therapeutics Enters into Exclusive License Agreement with Amneal Pharmaceuticals for IPX203

MONTREAL, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an...

Trading For This Specialty Pharma Company is up Following Second Quarter Results

This stock is almost a penny stock no longer, as shares moved close to the $5 threshold following the firm’s quarterly announcement. Leading pan-American (ex-US) specialty pharmaceutical...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.040.7604562737645.265.495.211690965.2823063CS
4-0.11-2.033271719045.415.595.21972115.35025738CS
120.11.923076923085.25.755.2794005.45611689CS
260.9221.004566214.385.754.35689395.2327969CS
52123.25581395354.35.754.28760614.94633408CS
156-0.15-2.752293577985.456.24.281703455.26363428CS
260-2.09-28.28146143447.398.884.282361376.06143941CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 22.08
(364.84%)
31.9M
NXLNexalin Technologies Inc
$ 1.50
(92.31%)
11.67M
CEROCERo Therapeutics Holdings Inc
$ 3.112
(90.92%)
24.08M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
KYCHKeyarch Acquisition Corporation
$ 12.30
(75.58%)
196.62k
BOLDBoundless Bio Inc
 14.25
(-76.24%)
767.63k
PMECPrimech Holdings Ltd
$ 1.2999
(-66.50%)
8.28M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.1816
(-44.45%)
21.92M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
NKLANikola Corporation
$ 1.035
(13.85%)
163.84M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
MARAMarathon Digital Holdings Inc
$ 22.56
(2.22%)
86.14M
AKANAkanda Corporation
$ 0.1166
(-29.29%)
80.34M

GUD Discussion

View Posts
sumotrader sumotrader 8 years ago
Loaded 1600 more shares today. GUD is about to take off.
👍️0
CommonCents4Dollars CommonCents4Dollars 9 years ago
This must be some sort of record,.. " the Company reported revenues of $109,608 and net income of $124,981,439."

http://www.gud-knight.com/en/knight-reports-fourth-quarter-and-year-ended-december-31-2014-results
👍️0
CommonCents4Dollars CommonCents4Dollars 9 years ago
Knight Therapeutics GUD.TO : Mackie Research starts with buy rating; target price of C$12

http://www.investorvillage.com/groups.asp?mb=6781&mn=83648&pt=msg&mid=14732670
👍️0
OneStepAhead OneStepAhead 9 years ago
On a tear
👍️0
CommonCents4Dollars CommonCents4Dollars 9 years ago
GOD is GUD. :)
👍️0
CommonCents4Dollars CommonCents4Dollars 9 years ago
KHTRF is the OTC Ticker for Americans
or
GUD on the TSX for Canadians


LONG on this one.
👍️0
CommonCents4Dollars CommonCents4Dollars 9 years ago
GUD is flying along nicely,.. Paladin II is in GUD hands, Goodman building another BEAST!
👍️0
OneStepAhead OneStepAhead 9 years ago
GUD Knight Therapeutics

Knight Therapeutics Inc. ("Knight" or the "Company") (TSX:GUD) today announced that it has entered into a bought deal agreement with a syndicate of underwriters led by GMP Securities L.P. and including Cormark Securities Inc., National Bank Financial Inc., Laurentian Bank Securities Inc., Bloom Burton & Co., Clarus Securities Inc., Mackie Research Capital Corporation and TD Securities Inc. (the "Underwriters"), pursuant to which the Underwriters have agreed to purchase 11,111,120 common shares of the Company (the "Common Shares") at a price of $6.75 per Common Share for gross proceeds to Knight of $75,000,060 (the "Offering"). In addition, the Underwriters will have the option, exercisable for a period of 30 days after the closing date, to acquire up to an aggregate of 1,666,668 additional Common Shares ($11,250,009) at the offering price to cover over-allotments, if any (the "Over-Allotment Option"). If the Over-Allotment Option is exercised in full, the total gross proceeds of the Offering shall be $86,250,069.

http://www.marketwired.com/press-release/knight-therapeutics-enters-into-agreement-75-million-bought-deal-common-shares-tsx-gud-1973898.htm
👍️0
OneStepAhead OneStepAhead 9 years ago
GUD Knight Therapeutics

After selling off his specialty pharmaceutical company Paladin Labs Inc. in a deal worth $3-billion, Montreal entrepreneur Jonathan Goodman is starting from scratch with a new drug distribution venture.

http://www.theglobeandmail.com/globe-investor/investment-ideas/a-fresh-stock-with-a-veteran-face/article17189152/
👍️0
Greedy G Greedy G 9 years ago
TNEN:

http://stockcharts.com/h-sc/ui?s=TNEN&p=D&b=5&g=0&id=p74917584188
👍️0

Your Recent History

Delayed Upgrade Clock